All In Biotech

Drug Trial Radar · NCT06610266

Efficacy and Safety of Weifuchun Tablet in Reversing Gastric Intestinal Metaplasia

Efficacy and Safety of Weifuchun Tablet in Reversing Gastric Intestinal Metaplasia: A Multi-center, Open-label, Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Feb 28, 2025

Primary completion

Dec 31, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Yongquan ShiAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to investigate the efficacy and safety of Weifuchun tablet in treating gastric intestinal metaplasia in Helicobacter pylori-negative adults. The main questions it aims to answer are: Does Weifuchun tablet promote the regression of gastric intestinal metaplasia in individuals without Helicobacter pylori infection? What medical problems do participants experience when taking Weifuchun tablet? Researchers will compare the effectiveness of Weifuchun tablet in treating gastric intestinal metaplasia with that of folic acid, as suggested by the Chinese consensus on management of gastric epithelial precancerous conditions and lesions (2020). Participants will: Take Weifuchun tablets or folic acid every day for 6 months. Visit the clinic once every 4 weeks for checkups and tests.

Conditions

  • Gastric Intestinal Metaplasia

Interventions

  • WeifuchunDrug

    Subjects will be instructed to take four tablets (1400mg) of Weifuchun three times daily, and visit the hospital every 4 weeks for evaluation of the subjective symptoms and to receive a new supply of medication.

  • Folic AcidDrug

    Subjects will be instructed to take one tablet (5mg) of folic acid three times daily, and visit the hospital every 4 weeks for evaluation of the subjective symptoms and to receive a new supply of medication.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The regression rate of gastric intestinal metaplasia based on OLGIM stage in different groups.Time frame: From enrollment to the end of treatment at 6 months.
  2. The progression rate of gastric intestinal metaplasia based on OLGIM stage in different groups.Time frame: From enrollment to the end of treatment at 6 months.

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Ankang Central Hospital

    Ankang, China · Recruiting

  • Tongchuan People's Hospital

    Tongchuan, China · Recruiting

  • Weinan Central Hospital

    Weinan, China · Recruiting

  • The 986th Hospital of Air Force Medical University

    Xi'an, China · Recruiting

  • Xijing hospital

    Xi'an, China · Recruiting

  • Xi'an Central Hospital

    Xi'an, China · Recruiting

  • Xi'an Honghui Hospital

    Xi'an, China · Recruiting

  • Xunyang People's Hospital

    Xuchang, China · Recruiting

  • Affiliated Hospital of Yan'an University

    Yanan, China · Recruiting

  • Shangluo Central Hospital

    Shangluo, Shaanxi, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.